GSK’s patent relay: can current medicines fund their replacements? London ordinary GSK.LSE/GBX; ISIN GB00BN7SWP63. Dated 30 October close: 1,855p (£18.55), not a live Sunday quote.
GSK research · AI Opinions · Fundamentals · Rankings / Strongest Buys
Q3 sales £8.89bn grew 4% AER/5% CER; Total EPS 38.50p fell 23% AER, while Core EPS 54.60p fell 1% AER/rose 1% CER. Core margin 34.60% was nearly flat as R&D rose. Specified adjusting items explain the Total/Core EPS gap; normal research and financing costs affect both measures. September net debt £20.74bn versus £14.45bn in December reflects acquisitions; factory capex alone understates scientific investment.
9M net operating cash £6.64bn; company FCF £4.89bn includes disposals and a special ViiV transaction. TTM company FCF £5.85bn removes the old nine months before adding the new nine months, counting each quarter once. Cash net of overdrafts: £3.21bn + £0.04bn accounting adjustment + £6.64bn operations − £9.96bn investing + £2.79bn financing − £0.04bn FX ≈ £2.68bn. Charges, cash paid and savings targets are distinct; £1.90bn annual savings by 2029 is a target.
Fixed 18 September 2027/2031 weighted prices £20.55/£26.50 imply 10.79%/42.86% cumulative price gains from £18.55. Future assumed cash 53p/333p across 3/19 payments gives 13.64%/60.81% gross cash-plus-price, before tax/fees, no reinvestment. Quarterly 17p/19p/17p/17p pattern assumes 70p annually; only 17p payable 7 January 2027 is declared. October’s paid 17p is excluded. Platform Strong Buy/Buy ratings use separate historical net-yield/reinvestment inputs.
Bull: replacement HIV, oncology and hepatitis B cash outpaces patent erosion. Bear: clinical setbacks, pricing, interest and restructuring drain cash. Both tails matter; base-path dispersion is not a stressed bull/bear forecast. Fourteen correlated AI contributions are not independent human analysts. The twenty-step path retains its June 2028 dip. Neladalkib is an ALK-targeted medicine for ALK-positive non-small-cell lung cancer, with a possible November/H2 decision. Eighteen Phase III studies are recruiting; four more on track keep the 2026 target at twenty-two. The June acquisition agreement was already known by the 5 July research baseline; July then brought completion, Jideytro approval and the 28 July savings plan. October adds newer results. Hibsago Japan approval was 24 August; US approval 20 October. Upstream display QA remains open, separate from primary checks.
Previously covered: Novo Nordisk24 audio / ▶video; Boston Scientific25 audio / ▶video; Medtronic27 audio / ▶video. Last-stock baseline: Proximus35 audio / ▶video.
Sources: Q3 results · official call · dividends · London close.
For the bigger picture, visit iPulse AI to explore our complete rankings of covered assets, discover the Strongest Buys, and see the research behind the ratings, all in one place. Primary research conducted through the iPulse AI platform by Future Edge Group. Like, comment and subscribe. We are publishing a new podcast every day of the week except Thursday. Stay tuned for the next podcast on RxSight.
This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit